C. Scott-Wilson

A randomised trial of fluticasone furoate/vilanterol (50/25 μg; 100/25 μg) on lung function in COPD.

E. Kerwin, A. Agustí, S. Rennard, 2013, Respiratory medicine.

A randomised, phase III trial of once-daily fluticasone furoate/vilanterol 100/25 μg versus once-daily vilanterol 25 μg to evaluate the contribution on lung function of fluticasone furoate in the combination in patients with COPD.

C. Crim, T. Siler, A. Nagai, 2017, Respiratory medicine.

Corrigendum to “Fluticasone furoate/vilanterol (100/25; 200/25 μg) improves lung function in COPD: A randomised trial” [Respir Med 107 (2013) 550–559]

F. Martinez, P. Calverley, L. Fabbri, 2013 .

Corrigendum to “A randomised trial of fluticasone furoate/vilanterol (50/25 μg; 100/25 μg) on lung function in COPD” [Respir Med, 107 (2013) 560–569]

E. Kerwin, A. Agustí, S. Rennard, 2013 .

Tolerability of a salmeterol xinafoate/fluticasone propionate hydrofluoroalkane metered-dose inhaler in adolescent and adult patients with persistent asthma: a 52-week, open-label, stratified, parallel-group, multicenter study.

P. Dorinsky, L. Boulet, P. Keith, 2007, Clinical therapeutics.

Fluticasone furoate/vilanterol (100/25; 200/25 μg) improves lung function in COPD: a randomised trial.

F. Martinez, P. Calverley, L. Fabbri, 2013, Respiratory medicine.

Efficacy and safety of 4 weeks' treatment with combined fluticasone furoate/vilanterol in a single inhaler given once daily in COPD: a placebo-controlled randomised trial

J. Lötvall, P. Bakke, C. Crim, 2012, BMJ Open.

A randomized trial of once-daily fluticasone furoate/vilanterol or vilanterol versus placebo to determine effects on arterial stiffness in COPD

J. Cockcroft, C. Crim, M. Dransfield, 2017, International journal of chronic obstructive pulmonary disease.

Efficacy and safety of fluticasone furoate/vilanterol or tiotropium in subjects with COPD at cardiovascular risk

C. Crim, A. Emmett, C. Scott-Wilson, 2015, International journal of chronic obstructive pulmonary disease.

Effects of fluticasone propionate and salmeterol hydrofluoroalkane inhalation aerosol on asthma-related quality of life.

H. Ortega, C. Scott-Wilson, L. Schoaf, 2009, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

Validation of the Summit Lab Score in Predicting Exacerbations of Chronic Obstructive Pulmonary Disease Among Individuals with High Arterial Stiffness

B. Horne, B. Miller, C. Crim, 2021, International journal of chronic obstructive pulmonary disease.